Most of the small speculative biotech stocks were slammed last week hard, but now that the economy has slowed down a bit in the second quarter, Jim Cramer took the time to circle back to an interesting pharma company that could present a new angle on women's health.
TherapeuticsMD is a pharmaceutical company geared towards specialization of hormone replacement therapies. And while it does also have a sideline business in prenatal vitamins, its main focus is to create formulations that deal with complications of menopause.
Since 1990 there have not been any new lower effective doses or new natural estrogen available for women. TherapeuticsMD is looking to change that, and Cramer considers the potential that could come from its pipeline to be huge.
In fact, he considers this $6 stock with a one billion market cap to be pretty cheap. So while the biotech sector has been very volatile recently, the "Mad Money" host was still intrigued by this company.
Could this angle on women's health bring in major bucks for investors? To find out, Cramer sat down with TherapeuticsMD co-founder and CEO Robert Finizio.